Sponsors (8)
The bill creates a regulatory pathway that could reduce foodborne illness and gives manufacturers clearer rules, but it raises compliance costs, restricts some existing animal-health tools and labeling communications, and limits public-health authority to mandate use during outbreaks.
Farmers and meat/dairy consumers gain a clear FDA approval pathway for non-therapeutic, GI-targeted feed/water additives that could reduce foodborne pathogens and make meat and dairy products safer.
Manufacturers and small animal-health businesses receive defined labeling and petition requirements, reducing regulatory uncertainty when developing these non-therapeutic additives.
Farmers and manufacturers may face higher compliance costs for additional testing, data generation, and labeling needed to secure approval under section 409, increasing financial burden especially on smaller operations.
Farmers could lose access to some currently effective animal-health tools (e.g., ionophores and certain drugs) that are explicitly excluded, which may limit options for controlling pathogens or managing production.
Manufacturers and producers are constrained from making therapeutic claims on labels and face misbranding penalties, which limits communication about benefits and raises enforcement risk for businesses.
Based on analysis of 2 sections of legislative text.
Creates an FDA food‑additive pathway for certain non‑therapeutic GI‑acting feed/water additives with petition, labeling, and misbranding rules and forbids mandating their use.
Introduced May 22, 2025 by Roger Wayne Marshall · Last progress May 22, 2025
Creates a new FDA-regulated category for certain non-therapeutic feed or drinking‑water additives that act only in an animal's gastrointestinal tract to change digestion byproducts, reduce foodborne pathogens, or alter the gut microbiome. It subjects those products to the food‑additive approval process with specific petition data requirements, labeling rules, and misbranding penalties, excludes clearly therapeutic drugs and related substances from the category, and bars the Department of Health and Human Services from requiring their use. Requires applicants to submit data showing the intended, non‑therapeutic effect and quantity, gives FDA authority to set the conditions under which an additive may achieve its intended effect and to deny petitions that fail to prove effectiveness, and mandates a specific label statement disallowing therapeutic claims; failure to include the label statement is treated as misbranding.